Expansion into beta thalassemia GBT Germany GmbH is actively developing treatments for beta thalassemia, presenting an opportunity to leverage this portfolio to target healthcare providers and institutions specializing in blood disorders.
Acquisition by Pfizer-BioNTech Following the $5.4 billion acquisition by Pfizer-BioNTech, there is potential for collaboration with the wider Pfizer network to introduce GBT's existing and upcoming treatments to a broader market segment.
Next-gen SCD treatments development GBT Germany GmbH's focus on developing the next generation of treatments for sickle cell disease (SCD) opens avenues to engage with pharmaceutical distributors and research institutions interested in cutting-edge therapies.
Phase 3 study launch The initiation of Phase 3 HOPE-KIDS 2 study by GBT presents an opportunity to engage with pediatric healthcare providers, researchers, and clinical trial networks to discuss potential collaboration and participation in the study.
ESG commitment and report launch GBT's dedication to environmental, social, and governance (ESG) practices, as highlighted in its inaugural report, can be leveraged to engage with socially responsible investors and institutions aligning with sustainable healthcare initiatives.
501
$100M$1B
436$50M$100M
334$50M$100M
1.5K$100M$1B
131$10M$50MGlobal Blood Therapeutics uses 8 technology products and services including Google Analytics, React, Backbone.js, and more. Explore Global Blood Therapeutics's tech stack below.
| Global Blood Therapeutics Email Formats | Percentage |
| FLast@gbt.com | 93% |
| Last@gbt.com | 3% |
| FirstL@gbt.com | 3% |
| FL@gbt.com | 1% |
| FLast@globalbloodtx.com | 86% |
| First.Last@globalbloodtx.com | 9% |
| LastFirst@globalbloodtx.com | 2% |
| LFirst@globalbloodtx.com | 2% |
| F.Last@globalbloodtx.com | 1% |
Biotechnology ResearchCalifornia, United States201-500 Employees
Global Blood Therapeutics (GBT) is now part of Pfizer, and we look forward to continuing our mission on behalf of people living with sickle cell disease. The Global Blood Therapeutics page will no longer be active or monitored. Please follow Pfizer for new content.
Company Overview
Media & News
Funding & FinancialsGlobal Blood Therapeutics has raised a total of $300M of funding over 7 rounds. Their latest funding round was raised on Dec 15, 2021 in the amount of $300M.
Global Blood Therapeutics's revenue is in the range of $50M$100M
Funding & FinancialsGlobal Blood Therapeutics has raised a total of $300M of funding over 7 rounds. Their latest funding round was raised on Dec 15, 2021 in the amount of $300M.
Global Blood Therapeutics's revenue is in the range of $50M$100M
1-888-653-2347 
support@leadiq.com